126 related articles for article (PubMed ID: 31076963)
1. Pam
Megías J; Martínez A; San-Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Albert-Bellver D; Carratalá A; Gozalbo D; López-Ginés C; Gil ML; Cerdá-Nicolás M
Invest New Drugs; 2020 Apr; 38(2):299-310. PubMed ID: 31076963
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide.
Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y
Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I; Kleijn A; Ju J; Jimenez-Cowell K; Fabro F; Klein M; Chi Yen RT; Balvers RK; Li Y; Stubbs AP; Kers TV; Kros JM; Lawler SE; Beerepoot LV; Kremer A; Idbaih A; Verreault M; Byrne AT; O'Farrell AC; Connor K; Biswas A; Salvucci M; Prehn JHM; Lambrechts D; Dilcan G; Lodi F; Arijs I; van den Bent MJ; Dirven CMF; Leenstra S; ; Lamfers MLM
Br J Cancer; 2023 Oct; 129(8):1327-1338. PubMed ID: 37620410
[TBL] [Abstract][Full Text] [Related]
5. Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent.
Chinyama HA; Wei L; Mokgautsi N; Lawal B; Wu ATH; Huang HS
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003585
[TBL] [Abstract][Full Text] [Related]
6. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract][Full Text] [Related]
7. Astrocytes Decreased the Sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082.
Pustchi SE; Avci NG; Akay YM; Akay M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998285
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs.
Safa AR; Saadatzadeh MR; Cohen-Gadol AA; Pollok KE; Bijangi-Vishehsaraei K
Genes Dis; 2015 Jun; 2(2):152-163. PubMed ID: 26137500
[TBL] [Abstract][Full Text] [Related]
9. Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome.
Skaga E; Kulesskiy E; Potdar S; Panagopoulos I; Micci F; Langmoen IA; Sandberg CJ; Vik-Mo EO
Transl Oncol; 2022 Dec; 26():101535. PubMed ID: 36115076
[TBL] [Abstract][Full Text] [Related]
10. Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
Sousa N; Geiß C; Bindila L; Lieberwirth I; Kim E; Régnier-Vigouroux A
BMC Cancer; 2023 Aug; 23(1):762. PubMed ID: 37587449
[TBL] [Abstract][Full Text] [Related]
11. Synergistic combination of chemo‑phototherapy based on temozolomide/ICG‑loaded iron oxide nanoparticles for brain cancer treatment.
Kwon YM; Je JY; Cha SH; Oh Y; Cho WH
Oncol Rep; 2019 Nov; 42(5):1709-1724. PubMed ID: 31436296
[TBL] [Abstract][Full Text] [Related]
12. The iron chelator and OXPHOS inhibitor VLX600 induces mitophagy and an autophagy-dependent type of cell death in glioblastoma cells.
Reisbeck L; Linder B; Tascher G; Bozkurt S; Weber KJ; Herold-Mende C; van Wijk SJL; Marschalek R; Schaefer L; Münch C; Kögel D
Am J Physiol Cell Physiol; 2023 Dec; 325(6):C1451-C1469. PubMed ID: 37899749
[TBL] [Abstract][Full Text] [Related]
13. Role of autophagy in regulation of glioma stem cells population during therapeutic stress.
Abbas S; Singh SK; Saxena AK; Tiwari S; Sharma LK; Tiwari M
J Stem Cells Regen Med; 2020; 16(2):80-89. PubMed ID: 33414584
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.
Xu D; Zhou D; Bum-Erdene K; Bailey BJ; Sishtla K; Liu S; Wan J; Aryal UK; Lee JA; Wells CD; Fishel ML; Corson TW; Pollok KE; Meroueh SO
ACS Chem Biol; 2020 Jun; 15(6):1424-1444. PubMed ID: 32243127
[TBL] [Abstract][Full Text] [Related]
15. A Highly Sensitive Cell-Based TLR Reporter Platform for the Specific Detection of Bacterial TLR Ligands.
Radakovics K; Battin C; Leitner J; Geiselhart S; Paster W; Stöckl J; Hoffmann-Sommergruber K; Steinberger P
Front Immunol; 2021; 12():817604. PubMed ID: 35087538
[TBL] [Abstract][Full Text] [Related]
16. Gliomagenesis is orchestrated by the Oct3/4 regulatory network.
Ignatova TN; Chaitin HJ; Kukekov NV; Suslov ON; Dulatova GI; Hanafy KA; Vrionis FD
J Neurosurg Sci; 2024 Apr; 68(2):148-156. PubMed ID: 34342203
[TBL] [Abstract][Full Text] [Related]
17. Identification of glioblastoma stem cell-associated lncRNAs using single-cell RNA-sequencing datasets.
Hazra R; Utama R; Naik P; Dobin A; Spector DL
bioRxiv; 2023 Jan; ():. PubMed ID: 36711961
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.
Couturier CP; Ayyadhury S; Le PU; Nadaf J; Monlong J; Riva G; Allache R; Baig S; Yan X; Bourgey M; Lee C; Wang YCD; Wee Yong V; Guiot MC; Najafabadi H; Misic B; Antel J; Bourque G; Ragoussis J; Petrecca K
Nat Commun; 2020 Jul; 11(1):3406. PubMed ID: 32641768
[TBL] [Abstract][Full Text] [Related]
19. A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells.
Dogra N; Singh P; Kumar A
Mol Neurobiol; 2024 Apr; ():. PubMed ID: 38619743
[TBL] [Abstract][Full Text] [Related]
20. Targeting the multidrug and toxin extrusion 1 gene (SLC47A1) sensitizes glioma stem cells to temozolomide.
Batara DC; Park SW; Kim HJ; Choi SY; Ohn T; Choi MC; Park SI; Kim SH
Am J Cancer Res; 2023; 13(9):4021-4038. PubMed ID: 37818053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
